> But last week, after reports that the company pressured its clinicians to prescribe medications for A.D.H.D., Cerebral received a grand jury subpoena from the U.S. attorney’s office for the Eastern District of New York, which is investigating possible violations of the Controlled Substances Act, according to a representative for the company. Cerebral has more than 200,000 patients.
> The investigation, which the representative said Cerebral intends to fully cooperate with, comes on the heels of accusations from former employees who said the company prescribed Adderall and Ritalin to treat A.D.H.D. without properly screening patients.
...
> Cerebral is only one of the dozens of mental health start-ups that took off in recent years. At the start of the pandemic, regulators relaxed rules around medical prescription of controlled substances, allowing clinicians to prescribe stimulants and other medications online without the need for an initial in-person evaluation, said Danielle Stutzman, a psychiatric pharmacist and spokeswoman for the College of Psychiatric and Neurologic Pharmacists, a professional organization of pharmacists.
> Those changes made it easier for people with A.D.H.D. to get access to treatments during lockdowns — but also opened the door for companies to prescribe and market drugs without the protocols that can accompany an in-person visit. The Wall Street Journal reported that Cerebral visits typically took only 30 minutes, during which time some clinicians felt pressure to prescribe stimulants.
Cerebral announced in May that they'd pause prescribing ADHD drugs,[1][2] then deleted the announcement by November.[3]
It's not the sole cause, as is the case most systemic problems - Teva Pharmaceuticals had a labor shortage for months that reduced production - but exacerbated a demand growth that had been fast since 2006, grew faster immediately before the pandemic, and then shifted in growth from children to adults under during the pandemic in line with the pandemic-inspired growth of telemedicine prescriptions.[1]
Teva's shortage is passing, but Alvogen, Rhodes Pharmaceuticals and SpecGX all remain short. Methylphenidates (Ritalin and Concerta) are also temporarily short as Adderall users switched off during the shortage.[4]
> But last week, after reports that the company pressured its clinicians to prescribe medications for A.D.H.D., Cerebral received a grand jury subpoena from the U.S. attorney’s office for the Eastern District of New York, which is investigating possible violations of the Controlled Substances Act, according to a representative for the company. Cerebral has more than 200,000 patients.
> The investigation, which the representative said Cerebral intends to fully cooperate with, comes on the heels of accusations from former employees who said the company prescribed Adderall and Ritalin to treat A.D.H.D. without properly screening patients.
...
> Cerebral is only one of the dozens of mental health start-ups that took off in recent years. At the start of the pandemic, regulators relaxed rules around medical prescription of controlled substances, allowing clinicians to prescribe stimulants and other medications online without the need for an initial in-person evaluation, said Danielle Stutzman, a psychiatric pharmacist and spokeswoman for the College of Psychiatric and Neurologic Pharmacists, a professional organization of pharmacists.
> Those changes made it easier for people with A.D.H.D. to get access to treatments during lockdowns — but also opened the door for companies to prescribe and market drugs without the protocols that can accompany an in-person visit. The Wall Street Journal reported that Cerebral visits typically took only 30 minutes, during which time some clinicians felt pressure to prescribe stimulants.
Cerebral announced in May that they'd pause prescribing ADHD drugs,[1][2] then deleted the announcement by November.[3]
It's not the sole cause, as is the case most systemic problems - Teva Pharmaceuticals had a labor shortage for months that reduced production - but exacerbated a demand growth that had been fast since 2006, grew faster immediately before the pandemic, and then shifted in growth from children to adults under during the pandemic in line with the pandemic-inspired growth of telemedicine prescriptions.[1]
Teva's shortage is passing, but Alvogen, Rhodes Pharmaceuticals and SpecGX all remain short. Methylphenidates (Ritalin and Concerta) are also temporarily short as Adderall users switched off during the shortage.[4]
1: https://www.drugtopics.com/view/adderall-shortage-continues-...
2: https://web.archive.org/web/20220504153953/https://cerebral....
3: https://web.archive.org/web/20221120002710/https://cerebral....
4: https://archive.ph/3SvUw